[en] BACKGROUND: To describe the medico-economic characteristics of Crohn's disease (CD), we implemented a multicenter study in France. METHODS: From 2004 to 2006, disease severity states, direct (hospital and extra hospital) and indirect costs were prospectively collected over 1 year in patients with CD naive from anti-tumor necrosis factor alpha (infliximab) at inclusion. Economic valorization was performed from the French Social Insurance perspective, and a statistical modeling over 10 years was performed. RESULTS: In 341 patients, the mean total costs of management were &OV0556;6024 per year (&OV0556;4675 for direct costs). As compared to patients in remission, costs were 4 to 6 times higher in patients in an active period and 19 times higher for patients requiring surgery (SURG). The most important expense items were medical and surgical hospitalizations (56% of total costs), including cost of infliximab (36% of hospitalization costs, i.e., 20% of total costs), indirect costs (22%), and drugs (11%). The statistical modeling over 10 years showed that most of the clinical course was spent in drug-responsive state (54%) with 26% of costs or in remission (32%) with 11% of costs; time spent in a SURG state was small (3.2%) but generated 48% of total costs. CONCLUSIONS: Before the introduction of self-injectable anti-tumor necrosis factor alpha, the most important expenses were supported by hospitalizations, explaining why the most costly states were for patients requiring SURG or dependent on inhospital administrated drugs. Projected data show that most time is spent in a stabilized state with appropriate treatments or in remission, and that costs associated with SURG are high.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Boschetti, Gilles
Nancey, Stephane
Daniel, Fady
Pariente, Benjamin
Lerebours, Eric
Duclos, Bernard
Bourreille, Arnaud
Cadiot, Guillaume
Fumery, Mathurin
Moreau, Jacques
Marteau, Philippe
Bouhnik, Yoram
Louis, Edouard ; Université de Liège > Département des sciences cliniques > Hépato-gastroentérologie
Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013; 7: 322-337
Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004; 53: 1471-1478
Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med. 2008; 50: 1261-1272
Feagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol. 2000; 95: 1955-1960
Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology. 2006; 131: 719-728
Cohen RD, Larson LR, Roth JM, et al. The cost of hospitalization in Crohn's disease. Am J Gastroenterol. 2000; 95: 524-530
Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999; 117: 49-57
Malone DC, Waters HC, Van Den Bos J, et al. A claims-based Markov model for Crohn's disease. Aliment Pharmacol Ther. 2010; 32: 448-458
Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol. 1992; 14: 318-327
Buchanan J, Wordsworth S, Ahmad T, et al. Managing the long term care of inflammatory bowel disease patients: the cost to European health care providers. J Crohns Colitis. 2011; 5: 301-316
Bernstein CN, Longobardi T, Finlayson G, et al. Direct medical cost of managing IBD patients: a Canadian population-based study. Inflamm Bowel Dis. 2012; 18: 1498-1508
Van Deen WK, Van Oijen MGH, Myers KD, et al. A nationwide 2010-2012 analysis of US health care utilization in inflammatory bowel diseases. Inflamm Bowel Dis. 2014; 20: 1747-1753
Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr Med Res Opin. 2008; 24: 319-328
Mesterton J, Jönsson L, Almer SHC, et al. Resource use and societal costs for Crohn's disease in Sweden. Inflamm Bowel Dis. 2009; 15: 1882-1890
Gibson PR, Weston AR, Shann A, et al. Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn's disease. J Gastroenterol Hepatol. 2007; 22: 1306-1312
Odes S, Vardi H, Friger M, et al. Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn's disease patients by Markov analysis. Aliment Pharmacol Ther. 2010; 31: 735-744
Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008; 135: 1907-1913
Burish J, Vardi H, Pedersen N, et al. Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom study. Inflamm Bowel Dis. 2015; 21: 121-131
Van Der Valk ME, Mangen MJJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFa therapy: results from the COIN study. Gut. 2014; 63: 72-79
Prenzler A, Bokemeyer B, von Der Schulenburg JM, et al. Health care costs and their predictors of inflammatory bowel diseases in Germany. Eur J Health Econ. 2011; 12: 273-283
Büsch K, da Silva SA, Holton M, et al. Sick leave and disability pension in inflammatory bowel disease: a systematic review. J Crohns Colitis. 2014; 8: 1362-1377
Juan J, Estiarte R, Colomé E, et al. Burden of illness of Crohn's disease in Spain. Dig Liver Dis. 2003; 35: 853-861
Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol. 1997; 32: 1134-1139
Stark R, König HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics. 2006; 24: 797-814
Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005; 54: 237-241
Sussman DA, Kubiliun N, Mulani PM, et al. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS). Inflamm Bowel Dis. 2012; 18: 2043-2055
Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004; 99: 91-96
Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008; 135: 1493-1499
Feagan BG, Reilly MC, Gerlier L, et al. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECISE 2 study. Aliment Pharmacol Ther. 2010; 31: 1276-1285